MADHAVBAUG Vaidya Sane Ayurved Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Madhavbaug reported a mixed H2 and FY25, demonstrating strong profitability improvements driven by stringent cost controls, particularly in employee and raw material expenses, leading to a 325% H2 EBITDA increase and 199% FY EBITDA increase. However, revenue saw a slight dip of 0.38% in H2 and 9.2% for the full year, attributed to reduced footfall. The company is aggressively expanding its hospital network, targeting increased patient footfall, and enhancing its brand visibility through new partnerships and marketing strategies, while also focusing on internal process improvements.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY25: revenue down 11.1%, net profit up 50.0% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|
| Revenue | 46 | 54 | 51 | 48 | 42 −9% | 48 −11% |
| EBITDA | 4 | 4 | 3 | 2 | 6 +50% | 9 +125% |
| Net profit | 3 | 2 | 1 | 1 | 4 +33% | 3 +50% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
